Correction to: Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial (Nature Medicine, (2024), 30, 9, (2517-2527), 10.1038/s41591-024-03076-6)

Steven M. Horwitz, Ajit J. Nirmal, Jahan Rahman, Ran Xu, Esther Drill, Natasha Galasso, Nivetha Ganesan, Theresa Davey, Helen Hancock, Leslie Perez, Catherine Maccaro, Alexandra Bahgat, Evan Marzouk, Elizabeth Cathcart, Alison Moskowitz, Ariela Noy, Anita Kumar, Eric Jacobsen, David C. Fisher, Neha Mehta-ShahYoun H. Kim, Michael Khodadoust, Nikita Kotlov, Anastasia Nikitina, Olga Kudryashova, Valeria Zubareva, Ksenia Zornikova, Nara Shin, Maria Sorokina, Sandrine Degryse, Ekaterina Postovalova, Aleksander Bagaev, Kinga Hosszu, Devin McAvoy, Jaap J. Boelens, Wenchao Wu, Zoe Ciantra, Jackson W. Appelt, Christopher Trevisani, Sam Amaka, David M. Weinstock, Santosha A. Vardhana

Research output: Contribution to journalComment/debate

Abstract

Correction to: Nature Medicinehttps://doi.org/10.1038/s41591-024-03076-6, published online 17 June 2024. In the version of this article initially published, there were two typographical errors in the SS (Sezary syndrome) row in the Arm A section of Table 3. The PRR (partial response rate) for both all patients and at MTD only should have been shown as “50 (2)” instead of “29 (2)” and “40 (2)”, respectively. The errors do not affect the conclusions of the study. The table has been updated in the HTML and PDF versions of the article.

Original languageEnglish
Pages (from-to)3778
Number of pages1
JournalNature medicine
Volume30
Issue number12
DOIs
StatePublished - Dec 2024

Fingerprint

Dive into the research topics of 'Correction to: Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial (Nature Medicine, (2024), 30, 9, (2517-2527), 10.1038/s41591-024-03076-6)'. Together they form a unique fingerprint.

Cite this